Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Bamias

Showing results (71-80 of 84) with videos related to

Pageof 9
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 11, 2003
Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology GroupA Bamias, G Aravantinos, C Deliveliotis, et al.
Clinical Genitourinary Cancer|August 27, 2024
Real-World Treatment Patterns in Patients With Metastatic Castration-Resistant Prostate Cancer in Greece: The PROSPECT StudyM Liontos, E Bournakis, A Bournakis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 28, 2005
Irinotecan or oxaliplatin combined with leucovorin and 5-fluorouracil as first-line treatment in advanced colorectal cancer: a multicenter, randomized, phase II studyH P Kalofonos, G Aravantinos, P Kosmidis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 9, 2017
Bevacizumab with or after chemotherapy for platinum-resistant recurrent ovarian cancer: exploratory analyses of the AURELIA trialA Bamias, E Gibbs, C Khoon Lee, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|May 23, 2025
Healthcare resource utilization and associated costs in patients with metastatic castration-resistant prostate cancer in GreeceE Bournakis, A Bournakis, D V Zolota, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 23, 2006
Paclitaxel and gemcitabine vs. paclitaxel and pegylated liposomal doxorubicin in advanced non-nasopharyngeal head and neck cancer. An efficacy and cost analysis randomized study conducted by the Hellenic Cooperative Oncology GroupG Fountzilas, P Papakostas, U Dafni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 9, 2012
Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03)A Bamias, U Dafni, A Karadimou, et al.
European Journal of Cancer (Oxford, England : 1990)|July 22, 2008
A randomised phase III trial of adjuvant radio-chemotherapy comparing Irinotecan, 5FU and Leucovorin to 5FU and Leucovorin in patients with rectal cancer: a Hellenic Cooperative Oncology Group StudyH P Kalofonos, A Bamias, A Koutras, et al.
ESMO Open|August 27, 2021
Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD studyR de Wit, C Wülfing, D Castellano, et al.
Diabetes Research and Clinical Practice|July 20, 2020
Demographic and clinical features of critically ill patients with COVID-19 in Greece: The burden of diabetes and obesityP Halvatsiotis, A Kotanidou, K Tzannis, et al.
Pageof 9

Showing results (71-80 of 84) with videos related to

Sort By:
Pageof 9
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 11, 2003
Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology GroupA Bamias, G Aravantinos, C Deliveliotis, et al.
Clinical Genitourinary Cancer|August 27, 2024
Real-World Treatment Patterns in Patients With Metastatic Castration-Resistant Prostate Cancer in Greece: The PROSPECT StudyM Liontos, E Bournakis, A Bournakis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 28, 2005
Irinotecan or oxaliplatin combined with leucovorin and 5-fluorouracil as first-line treatment in advanced colorectal cancer: a multicenter, randomized, phase II studyH P Kalofonos, G Aravantinos, P Kosmidis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 9, 2017
Bevacizumab with or after chemotherapy for platinum-resistant recurrent ovarian cancer: exploratory analyses of the AURELIA trialA Bamias, E Gibbs, C Khoon Lee, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|May 23, 2025
Healthcare resource utilization and associated costs in patients with metastatic castration-resistant prostate cancer in GreeceE Bournakis, A Bournakis, D V Zolota, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 23, 2006
Paclitaxel and gemcitabine vs. paclitaxel and pegylated liposomal doxorubicin in advanced non-nasopharyngeal head and neck cancer. An efficacy and cost analysis randomized study conducted by the Hellenic Cooperative Oncology GroupG Fountzilas, P Papakostas, U Dafni, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 9, 2012
Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03)A Bamias, U Dafni, A Karadimou, et al.
European Journal of Cancer (Oxford, England : 1990)|July 22, 2008
A randomised phase III trial of adjuvant radio-chemotherapy comparing Irinotecan, 5FU and Leucovorin to 5FU and Leucovorin in patients with rectal cancer: a Hellenic Cooperative Oncology Group StudyH P Kalofonos, A Bamias, A Koutras, et al.
ESMO Open|August 27, 2021
Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD studyR de Wit, C Wülfing, D Castellano, et al.
Diabetes Research and Clinical Practice|July 20, 2020
Demographic and clinical features of critically ill patients with COVID-19 in Greece: The burden of diabetes and obesityP Halvatsiotis, A Kotanidou, K Tzannis, et al.
Pageof 9